Evidence map›Paper›PMID 34466049›Full record

ArticleEye and brain2021

Efficacy and Safety of Proton Beam Therapy for Primary Optic Nerve Sheath Meningioma.

Rabih Hage, Claire Alapetite, Hervé Brisse, Kevin Zuber, Augustin Lecler, Guillaume Lot, Caroline Le Guerinel, Catherine Vignal-Clermont, Herve Boissonnet

Open access · goldAbstract readCase Reports
In one paragraph

Article in Eye and brain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rabih HageNeuro-ophthalmology Department, Hôpital Fondation A. de Rothschild, Paris, France.ORCID 0000-0002-1245-323X
Claire AlapetiteRadiation Oncology Department, and Proton Center Institut Curie, Paris-Orsay, France.
Hervé BrisseImaging Department, Institut Curie, Paris, France.ORCID 0000-0003-2794-5875
Kevin ZuberDepartment of Statistics and Clinical Research, Hôpital Fondation A. de Rothschild, Paris, France.
Augustin LeclerRadiology Department, Hôpital Fondation A. de Rothschild, Paris, France.ORCID 0000-0001-7869-1815
Guillaume LotNeurosurgery Department, Hôpital Fondation A. de Rothschild, Paris, France.
Caroline Le GuerinelNeurosurgery Department, Hôpital Fondation A. de Rothschild, Paris, France.
Catherine Vignal-ClermontNeuro-ophthalmology Department, Hôpital Fondation A. de Rothschild, Paris, France.ORCID 0000-0003-0292-8905
Herve BoissonnetNeurosurgery Department, Hôpital Fondation A. de Rothschild, Paris, France.
Fondation de Rothschild · FRInstitut Curie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeManagement of optic nerve sheath meningiomas (ONSM) remains challenging. Photon radiation therapy (PhRT) is the most common treatment for sight-threatening ONSM. Proton beam therapy (PBT) is less commonly used because it is more expensive and because there are questions about its efficacy specifically in relation to ONSM. PBT has the theoretical advantage of reducing radiation exposure to adjacent structures. We report the visual outcome of patients with primary ONSM managed at the Fondation Ophtalmologique Adolphe de Rothschild, Paris, France, and treated with PBT at the Centre de Protonthérapie, Institut Curie, Orsay, France.

methodsWe conducted a retrospective review of all patients with primary ONSM who received PBT (either by itself or following surgery) between January 2006 and January 2019. Neuro-ophthalmic examinations were performed at presentation and after radiotherapy, and, when applicable, after surgery. Meningiomas were measured at the time of diagnosis and at each follow-up MRI examination.

resultsSixty patients (50 women, 10 men; mean age, 45.2±11.1y) were included, of whom 29 underwent surgery. At presentation, 52 (87%) of them had decreased vision (average visual acuity: 0.6 logMAR). Fundus examination showed optic disc swelling (n=27; 46.5%), optic disc pallor (n=22; 37.9%), optic disc cupping (n=2; 3.4%), opto-ciliary shunt (n=8; 13.8%), or choroidal folds (n=5; 8.6%). Otherwise, it was unremarkable (n=7; 12.1%). After treatment, visual function was stable overall. Fundus examination showed pallor (n=47; 83.9%), swelling (n=3; 5.4%), or cupping (n=2; 3.4%) of the optic disc, or was unremarkable (n=5; 8.9%). The visual field of 8 patients worsened, while 3 developed asymptomatic retinal hemorrhages. Tumor shrunk significantly in 8 patients at 1 year after PBT and remained stable in size in all others. Patients with opto-ciliary shunts had significantly worse visual outcome than other patients. Retinal abnormalities were observed in 11 patients during follow-up.

conclusionPBT alone or in association with surgery appears to be a safe and efficient treatment for ONSM, reducing the tumor size and stabilizing visual function. The risk of developing radiation retinopathy seems to be higher when patients had upfront surgery.

Indexed as

brain tumorcompressive optic neuropathyONSMoptic nerve sheath meningiomaopto-ciliary shuntPBTproton beam therapyradiation retinopathyRONvisual loss

Identifiers

PMID34466049
PMCPMC8402992
OpenAlexW3195006883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.